文献速递泌尿生殖与妇科肿瘤放疗

临床细胞周期风险评分与放疗后转移相关并指导何时免去联合雄激素剥夺治疗

The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-10-03

这项回顾性多机构队列研究纳入741例局限期NCCN中危、高危和极高危前列腺癌患者,评估临床细胞周期风险(CCR)评分对接受剂量递增放疗联合或不联合雄激素剥夺治疗(ADT)后转移风险的预后能力。结果显示CCR评分每单位风险比2.22,优于NCCN风险分组、CAPRA评分或CCP评分单独使用。CCR评分低于多模态阈值2.112的患者10年转移风险为3.7%,高于阈值者为21.24%;低于阈值者接受单纯放疗与放疗联合ADT的10年转移风险均为3.7%。

要点

  • CCR评分可准确预后剂量递增放疗后转移风险,每单位HR 2.22(95%CI 1.71-2.89,P<.001)。
  • CCR评分预后优于NCCN风险分组、CAPRA评分或CCP评分单独使用。
  • CCR评分低于2.112者10年转移风险3.7%,加ADT未显著降低该风险。

核心结论

  • CCR评分能准确且精确地预后接受剂量递增放疗联合或不联合ADT男性的转移风险。
  • 对于CCR评分低于多模态阈值2.112的男性,加用ADT可能不会显著降低其10年转移风险。

研究设计与样本

  • 回顾性、多机构队列研究,纳入741例局限期NCCN中危、高危和极高危前列腺癌男性。
  • 患者接受剂量递增放疗联合或不联合ADT,主要结局为至转移时间。

主要发现

  • CCR评分每单位风险比为2.22(95%CI 1.71-2.89;P<.001)。
  • CCR评分预后转移优于NCCN风险分组(CCR P<.001;NCCN P=.46)、CAPRA评分(CCR P=.002;CAPRA P=.59)或CCP评分(CCR P<.001;CCP P=.59)单独使用。
  • 双变量分析中,校正ADT versus 无ADT(HR 2.18;95%CI 1.61-2.96;P<.001)、ADT持续时间作为连续变量(HR 2.11;95%CI 1.59-2.79;P<.001)或ADT给予时长处于或低于各NCCN风险组推荐时长(HR 2.19;95%CI 1.69-2.86;P<.001)后,CCR评分仍具有高度预后价值。
  • CCR评分低于或高于多模态阈值2.112的男性,10年转移风险分别为3.7%和21.24%。
  • 低于阈值者接受单纯放疗的10年转移风险为3.7%,接受放疗联合ADT的10年转移风险亦为3.7%。

关键数值与推荐

  • 多模态阈值为CCR评分2.112,低于或高于该阈值的10年转移风险分别为3.7%和21.24%。

临床怎么用

  • 对于接受剂量递增放疗的前列腺癌男性,可用CCR评分预后转移风险并辅助判断是否加用ADT。
  • CCR评分低于2.112者加用ADT可能不显著降低10年转移风险,可考虑免去联合ADT。

局限性

  • 回顾性研究设计。
  • 多机构队列,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The clinical cell-cycle risk (CCR) score, which combines the University of California, San Francisco's Cancer of the Prostate Risk Assessment (CAPRA) and the cell cycle progression (CCP) molecular score, has been validated to be prognostic of disease progression for men with prostate cancer. This study evaluated the ability of the CCR score to prognosticate the risk of metastasis in men receiving dose-escalated radiation therapy (RT) with or without androgen deprivation therapy (ADT). METHODS AND MATERIALS: This retrospective, multi-institutional cohort study included men with localized National Comprehensive Cancer Network (NCCN) intermediate-, high-, and very high-risk prostate cancer (N = 741). Patients were treated with dose-escalated RT with or without ADT. The primary outcome was time to metastasis. RESULTS: The CCR score prognosticated metastasis with a hazard ratio (HR) per unit score of 2.22 (95% confidence interval [CI], 1.71-2.89; P < .001). The CCR score better prognosticated metastasis than NCCN risk group (CCR, P < .001; NCCN, P = .46), CAPRA score (CCR, P = .002; CAPRA, P = .59), or CCP score (CCR, P < .001; CCP, P = .59) alone. In bivariable analyses, CCR score remained highly prognostic when accounting for ADT versus no ADT (HR, 2.18; 95% CI, 1.61-2.96; P < .001), ADT duration as a continuous variable (HR, 2.11; 95% CI, 1.59-2.79; P < .001), or ADT given at or below the recommended duration for each NCCN risk group (HR, 2.19; 95% CI, 1.69-2.86; P < .001). Men with CCR scores below or above the multimodality threshold (CCR score, 2.112) had a 10-year risk of metastasis of 3.7% and 21.24%, respectively. Men with below-threshold scores receiving RT alone had a 10-year risk of metastasis of 3.7%, and for men receiving RT plus ADT, the 10-year risk of metastasis was also 3.7%. CONCLUSIONS: The CCR score accurately and precisely prognosticates metastasis and adds clinically actionable information relative to guideline-recommended therapies based on NCCN risk in men undergoing dose-escalated RT with or without ADT. For men with scores below the multimodality threshold, adding ADT may not significantly reduce their 10-year risk of metastasis.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tward J, Lenz L, Flake DD, et al. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. Int J Radiat Oncol Biol Phys. 2021. PMID: 34610388. doi:10.1016/j.ijrobp.2021.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。